CYTOMEGALOVIRUS INFECTION TREATMENT AND DIAGNOSIS MARKET ANALYSIS

Cytomegalovirus Infection Treatment And Diagnosis MarketSize and Trends

Cytomegalovirus infection market: Treatment approach

People diagnosed with high risk of CMV infection may be given anti-viral medications to prevent the disease to get in to active stage. There is no cure available for treating the CMV infection. Ganciclovir, Val ganciclovir, Cidofovir, Valacyclovir and Foscarnet are few major anti-viral medications prescribed. In some cases, CMV immune globulin contains antibodies (proteins) may be prescribed to prevent CMV infection. There are certain products in pipeline which includes Cytovir CMV, Letermovir, CytoTect CP 70, Brincidofovir and ASP0113, commercialization of which is expected to fuel the global CMV infection treatment and diagnosis market growth in the near future.

Vital statistics for the global cytomegalovirus infection treatment and diagnosis market

Besides, diagnosis of new CMV cases would be a propelling factor for global cytomegalovirus infection treatment and diagnosis market. The Public Health Agency of Canada estimates that 40%-100% of the global population have CMV antibody present in their body. Immunocompromised patients (HIV, organ transplant), premature infants, newborns and with congenital CMV are at high risk of developing serious illness with CMV infection.

According to the Centers for Disease Control and Prevention (CDC), one in every 150 infants are born with congenital cytomegalovirus (CMV) infection in the U.S. However, only one in five infants infected with CMV have long term health problems. Prevailing infection rates and demand for effective treatment therapies would be thrusting the cytomegalovirus infection treatment and diagnosis market growth.

Market- Trends

Besides, diagnosis of new CMV cases would be a propelling factor for global cytomegalovirus infection treatment and diagnosis market. The Public Health Agency of Canada estimates that 40%-100% of the global population have CMV antibody present in their body. Immunocompromised patients (HIV, organ transplant), premature infants, newborns and with congenital CMV are at high risk of developing serious illness with CMV infection.

According to the Centers for Disease Control and Prevention (CDC), one in every 150 infants are born with congenital cytomegalovirus (CMV) infection in the U.S. However, only one in five infants infected with CMV have long term health problems.

Prevailing infection rates and demand for effective treatment therapies would be thrusting the cytomegalovirus infection treatment and diagnosis market growth.